Andexanet alfa

Medical uses

Andexanet alfa is used to stop life-threatening or uncontrollable bleeding in people who are taking rivaroxaban or apixaban.

Studies in healthy volunteers show that the molecule binds factor Xa inhibitors and counters their anti-Xa-activity. The first published clinical trial was a prospective, open label, single group study. This study reports results on 352 people and demonstrates a reduction of anti-Xa-activity while also showing an excellent or good hemostatic efficacy in 82%. While people who were expected to die in 30 days were excluded from the study, 14% of participants died. There was no relationship between hemostatic efficacy and reduced anti-Xa-activity. The FDA demanded a randomised clinical trial which resulted in publication in 2024. The ANNEXA-I trial included 530 patients with intracerebral hemorrhage who were receiving factor Xa inhibitors. Andexanet resulted in better control of hematoma expansion than usual care, but was associated with thrombotic events, including ischemic stroke. ANNEXA-I did not have sufficient power or information to draw conclusions about the effect of andexanet on mortality, clinical deterioration, or the need for rescue therapy.

Adverse effects

Common side effects include pneumonia and urinary tract infections. Severe side effects may include blood clots or cardiac arrest.

Andexanet alfa has a boxed warning that it is associated with arterial and venous blood clots, ischemic events, cardiac arrest, and sudden deaths.

Pharmacology

Mechanism of action

Andexanet alfa is a biologic agent, a recombinant modified version of human activated factor X (FXa). Andexanet alfa differs from native FXa due to the removal of a 34 residue fragment that contains the Gla domain. This modification reduces andexanet alfa's anticoagulant potential. Additionally, a serine to alanine (S419A) mutation in the active site eliminates its activity as a prothrombin to thrombin catalyst, but still allows the molecule to bind to FXa inhibitors. FXa inhibitors bind to andexanet alfa with the same affinity as to natural FXa. As a consequence, in the presence of andexanet alfa, natural FXa is partially freed, which can lead to effective hemostasis. In other words, it acts as a decoy receptor. Andexanet alfa reverses effect of all anticoagulants that act directly through FXa or by binding antithrombin III. The drug is not effective against factor IIa inhibitor dabigatran. Its activity is measured using the anti-Xa test, which is utilized to determine the amount of available factor Xa for coagulation

History

It was approved in the United States in 2018 based on data from two phase III studies on reversing the anticoagulant activity of FXa inhibitors rivaroxaban and apixaban in healthy volunteers. As a condition of its accelerated approval, the ANNEXA-I study was conducted comparing it to other currently used reversal agents ("usual care").

Andexanet alfa was voluntarily withdrawn from the market by the manufacturer following safety concerns expressed by the FDA. Production and distribution was ended December 22, 2025.

Society and culture

Economics

Initial pricing (AWP) is $58,000 per reversal (800 mg bolus + 960 mg infusion, $3,300 per 100 mg vial) which is higher than reversal agents for other DOAC agents (idarucizumab for use in dabigatran reversal is $4,200 per reversal).

References

References

1. (12 July 2023). "Andexxa APMDS".
2. (28 July 2023). "Andexxa (AstraZeneca Pty Ltd)".
3. (19 December 2023). "AusPAR: Andexxa".
4. (16 June 2023). "Details for: Ondexxya".
5. "Summary Basis of Decision (SBD) for Ondexxya".
6. (26 October 2023). "Notice: Multiple additions to the Prescription Drug List (PDL) [2023-08-30]".
7. (21 September 2020). "Andexxa- andexanet alfa injection, powder, lyophilized, for solution".
8. Ondexxya EPAR. (27 June 2019). "Ondexxya".
9. "Andexxa Monograph for Professionals".
10. (March 2013). "Antidotes edge closer to reversing effects of new blood thinners". Nature Medicine.
11. "Update on the Safety of Andexxa - FDA Safety Communication – December 18, 2025".
12. (April 2019). "Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors". The New England Journal of Medicine.
13. (11 February 2019). "Andexanet Alfa: More garbage science in the New England Journal of Medicine". First10EM blog.
14. {{ClinicalTrialsGov. NCT03661528. A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor
15. (May 2024). "Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage". The New England Journal of Medicine.
16. (May 2024). "Reversing Oral Anticoagulation in Intracerebral Hemorrhage". The New England Journal of Medicine.
17. (16 November 2008). "Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors.". Blood.
18. (13 September 2017). "Reversing factor Xa inhibitors - clinical utility of andexanet alfa". Journal of Blood Medicine.
19. (April 2013). "A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa". Nature Medicine.
20. (23 December 2013). "Neue Wirkstoffe – Andexanet Alfa". Österreichische Apothekerzeitung.
21. (October 2019). "Andexanet Alfa for Urgent Reversal of Apixaban Before Aortic Surgery Requiring Cardiopulmonary Bypass: A Case Report". A&A Practice.
22. (December 2015). "Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity". The New England Journal of Medicine.
23. {{ClinicalTrialsGov. NCT03661528. Trial of Andexanet in ICH Patients Receiving an Oral FXa Inhibitor
24. (24 May 2018). "Lexi Comp Drug Information Online".